Australian Pharmaceutical Patents Expiring December 2013

Below is a report from IP Organisers (an independent service company of Phillips Ormonde Fitzpatrick) detailing Australian Pharmaceutical Patents which will expire in the next month.

ip org 

Australian Pharmaceutical Patents

Expiring December 2013

Active Ingredient Indapamide hemihydrate
Chemical Name 4-chloro-N(2-methyl-1-indolinyl)-3-sulphamoyl benzamide hemihydrate
Chemical Structure  dec 1
Australian Patent AU-B-651894
Expiry Date 7 December 2013
Patent Assignee Les Laboratoires Servier
Title Matrix tablet permitting the sustained release of indapamide after oral administration
Abstract The invention relates to a matrix tablet for the sustained release of indapamide which ensures a continuous and uniform release of the active principle after oral administration.
Australian Register of Therapeutic Goods ARTG ID 66849
Consumer Medicine Information Natrilix SR (indapamide hemihydrate)
Product Information Natrilix SR (indapamide hemihydrate)
Active Ingredient Hyaluronic Acid
Trade Name Hylaform/Synvisc
Chemical Name Hyaluronic Acid
Chemical Structure  dec 2
Australian Patent AU-B-629467
Expiry Date 11 December 2013
Patent Assignee Genzyme Biosurgery Corporation
Title Biocompatible viscoelastic gel slurries, their preparation and use
Abstract Biocompatible viscoelastic gel slurries formed from a polymeric gel, preferably a hyaluronan or a derivative thereof such as hylan swollen in an aqueous medium and a fluid phase which is an aqueous solution of a polymer which may also but not necessarily be a hyaluronan or derivative thereof. Also disclosed are methods of making such slurries, controlling their rheological properties and the uses thereof.
Australian Register of Therapeutic Goods ARTG ID 159219
Consumer Medicine Information
Product Information
Active Ingredient Gadobutrol
Trade Name Gadovist
Chemical Name 10-(2,3-Dihydroxy-1-hydroxymethylpropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, Gd-Complex
Chemical Structure  dec 3
Australian Patent AU-B-647091
Expiry Date 2 December 2013
Patent Assignee Schering Aktiengesellschaft
Title 1, 4, 7, 10-tetraazacyclodedecane butyltriols, processes for their production and pharmaceutical agents containing them
Abstract 1,4,7,10-Tetraazacyclododecane-butyltriols of the general formula IA in which R<1> independently of one another denotes hydrogen or a metal ion equivalent and R<2> denotes a butyltriol radical, and their salts with organic or inorganic bases or amino acids are useful pharmaceutical agents.
Australian Register of Therapeutic Goods ARTG ID 67045ARTG ID 67046ARTG ID 67047ARTG ID 67048
Consumer Medicine Information Gadovist (gadobutrol)
Product Information Gadovist (gadobutrol)
Active Ingredient Omalizumab
Trade Name Xolair
Chemical Name Recombinant DNA-derived humanised monoclonal antibody
Chemical Structure
Australian Patent AU-C-618317
Expiry Date 29 December 2013
Patent Assignee Tanox Biosystems, Inc.
Title Unique antigenic epitopes on IgE-bearing B lymphocytes
Abstract Unique antigenic epitopes of IgE (designated ige.b1 which are present on IgE-bearing B lymphocytes but not basophils are described. One class of ige.b1 epitopes are at or near the FcεR binding site on IgE. Another class of ige.b1 epitopes are associated with the extracellular segment of the domain of ε chains which anchor IgE to the B cell membrane (ε.mb/ec)). Monoclonal antibodies which bind to the ige.b1 epitopes are useful to treat IgE-mediated allergies. The monoclonal antibodies, either alone or as cytotoxin-conjugated immunotoxins, can be used to reduce or deplete IgE-producing B cells in allergy sufferers. Monoclonal antibodies against the idiotypes of the ige.b1 specific antibodies or peptides expressing the epitopes can be used to actively immunize allergy sufferers to attain the same results of administering the monoclonal antibodies.
Australian Register of Therapeutic Goods ARTG ID 82744
Consumer Medicine Information Xolair (omalizumab)
Product Information Xolair (omalizumab)

For further information please contact Rodney Chiang-Cruise or Aaron McMillan at IP Organisers Pty Ltd